Combination of Radiotherapy and Immune Checkpoint Inhibitors

Seminars in Radiation Oncology

Volumn 25, Issue 1, 2015, Pages 28-33

  Pilones, Karsten A ^a   Vanpouille Box, Claire ^a   Demaria, Sandra ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; PEPTIDE VACCINE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR VACCINE;

ANTIGEN PRESENTING CELL; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; HUMAN; IONIZING RADIATION; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR REGRESSION; TUMOR REJECTION; ADJUVANT THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES; RADIATION RESPONSE;

CELL DEATH; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RADIATION, IONIZING; RADIOTHERAPY, ADJUVANT; TUMOR MICROENVIRONMENT;

EID: 84919475564     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2014.07.004     Document Type: Review

References (76)

1. Vigneron, Stroobant V., Van den Eynde B.J., et al. Database of T cell-defined human tumor antigens: The 2013 update. Cancer Immun 2013, 13:15.
2. Klebanoff C.A., Acquavella N., Yu Z., et al. Therapeutic cancer vaccines: are we there yet?. Immunol Rev 2011, 239:27-44.
3. Mittal D., Gubin M.M., Schreiber R.D., et al. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014, 27C:16-25.
4. Matsushita H., Vesely M.D., Koboldt D.C., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
5. Castle J.C., Kreiter S., Diekmann J., et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012, 72:1081-1091.
6. Segal N.H., Parsons D.W., Peggs K.S., et al. Epitope landscape in breast and colorectal cancer. Cancer Res 2008, 68:889-892.
7. Buckowitz A., Knaebel H.P., Benner A., et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer 2005, 92:1746-1753.
8. Vesely M.D., Kershaw M.H., Schreiber R.D., et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011, 29:235-271.
9. Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013, 14:1014-1022.
10. Ji R.-R., Chasalow S.D., Wang L., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012, 61:1019-1031.
11. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
12. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
13. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med 2013, 369:122-133.
14. Postow M.A., Callahan M.K., Wolchok J.D. The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?. Clin Cancer Res 2012, 18:1821-1823.
15. Eriksson D., Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol 2010, 31:363-372.
16. Golden E.B., Pellicciotta I., Demaria S., et al. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2012, 2:88.
17. Golden E.B., Francis D., Pellicciotta I., et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. OncoImmunology 2014, 3:e28518.
18. Tesniere A., Panaretakis T., Kepp O., et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008, 15:3-12.
19. Ghiringhelli F., Apetoh L., Tesniere A., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009, 15:1170-1178.
20. Burnette B.C., Liang H., Lee Y., et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 2011, 71:2488-2496.
21. Demaria S., Formenti S.C. Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol 2007, 83:819-825.
22. Matsumura S., Wang B., Kawashima N., et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008, 181:3099-3107.
23. Lugade A.A., Sorensen E.W., Gerber S.A., et al. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008, 180:3132-3139.
24. Lugade A.A., Moran J.P., Gerber S.A., et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005, 174:7516-7523.
25. Reits E.A., Hodge J.W., Herberts C.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006, 203:1259-1271.
26. Chakraborty M., Abrams S.I., Camphausen K., et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003, 170:6338-6347.
27. Ruocco M.G., Pilones K.A., Kawashima N., et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves anti-tumor effects. J Clin Invest 2012, 122:3718-3730.
28. Kwilas A.R., Donahue R.N., Bernstein M.B., et al. In the field: Exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol 2012, 2:104.
29. Gulley J.L., Arlen P.M., Bastian N., et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005, 11:3353-3362.
30. Formenti S.C., Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009, 10:718-726.
31. + T cells: Changing strategies for cancer treatment. Blood 2009, 114:589-595.
32. Postow M.A., Callahan M.K., Barker C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931.
33. Stamell E.F., Wolchok J.D., Gnjatic S., et al. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2013, 85:293-295.
34. Hiniker S.M., Chen D.S., Reddy S., et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 2012, 5:404-407.
35. Demaria S., Kawashima N., Yang A.M., et al. Immune-mediated inhibition of metastases following treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005, 11:728-734.
36. Dewan M.Z., Galloway A.E., Kawashima N., et al. Fractionated but not single dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15:5379-5388.
37. Tivol E.A., Borriello F., Schweitzer A.N., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
38. Waterhouse P., Penninger J.M., Timms E., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-988.
39. Acuto O., Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003, 3:939-951.
40. van der Merwe P.A., Bodian D.L., Daenke S., et al. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997, 185:393-403.
41. Collins A.V., Brodie D.W., Gilbert R.J., et al. The interaction properties of costimulatory molecules revisited. Immunity 2002, 17:201-210.
42. Lee K.M., Chuang E., Griffin M., et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998, 282:2263-2266.
43. Marengere L.E., Waterhouse P., Duncan G.S., et al. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996, 272:1170-1173.
44. Schneider H., Downey J., Smith A., et al. Reversal of the TCR stop signal by CTLA-4. Science 2006, 313:1972-1975.
45. +) T cells. J Exp Med 1998, 188:1849-1857.
46. Walunas T.L., Lenschow D.J., Bakker C.Y., et al. Ctla-4 can function as a negative regulator of T-cell activation. Immunity 1994, 1:405-413.
47. Linsley P.S., Brady W., Urnes M., et al. Ctla-4 is a 2nd receptor for the B-Cell activation antigen-B7. J Exp Med 1991, 174:561-569.
48. Qureshi O.S., Zheng Y., Nakamura K., et al. Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332:600-603.
49. Wang J., Yoshida T., Nakaki F., et al. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A 2005, 102:11823-11828.
50. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012, 24:207-212.
51. Youngnak P., Kozono Y., Kozono H., et al. Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun 2003, 307:672-677.
52. Lee S.J., Jang B.C., Lee S.W., et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006, 580:755-762.
53. Cho H.Y., Lee S.W., Seo S.K., et al. Interferon-sensitive response element (ISRE) is mainly responsible for IFN-alpha-induced upregulation of programmed death-1 (PD-1) in macrophages. Biochim Biophys Acta 2008, 1779:811-819.
54. Kinter A.L., Godbout E.J., McNally J.P., et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008, 181:6738-6746.
55. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
56. Zhang Y., Wang L., Li Y., et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 2014, 7:567-573.
57. Thompson R.H., Kuntz S.M., Leibovich B.C., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006, 66:3381-3385.
58. Taube J.M., Anders R.A., Young G.D., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4:127ra137.
59. Azuma T1 Y.S., Zhu G., Flies A.S., et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008, 111:3635-3643.
60. Abiko K., Mandai M., Hamanishi J., et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 2013, 19:1363-1374.
61. Hirano F., Kaneko K., Tamura H., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005, 65:1089-1096.
62. Leach D., Krummel M., Allison J.P. Enhancement of anti-tumor immunity by CTLA4-blockade. Science 1996, 271:1734-1736.
63. Peggs K.S., Quezada S.A., Allison J.P. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008, 224:141-165.
64. van Elsas A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190:355-366.
65. Castle J.C., Kreiter S., Diekmann J., et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012, 72:1081-1091.
66. Golden E.B., Demaria S., Schiff P.B., et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013, 1:365-372.
67. Strome S.E., Dong H., Tamura H., et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003, 63:6501-6505.
68. Iwai Y., Ishida M., Tanaka Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002, 99:12293-12297.
69. Pilon-Thomas S., Mackay A., Vohra N., et al. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 2010, 184:3442-3449.
70. + T cells during recurrence of melanoma. J Immunol 2013, 190:4899-4909.
71. Okudaira K., Hokari R., Tsuzuki Y., et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol 2009, 35:741-749.
72. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
73. Zeng J., See A.P., Phallen J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013, 86:343-349.
74. Deng L., Liang H., Burnette B., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014, 124:687-695.
75. Sakuishi K., Jayaraman P., Behar S.M., et al. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol 2011, 32:345-349.
76. Sierro S., Romero P., Speiser D.E. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 2011, 15:91-101.